Slave, I can understand your position, but if you are right about the UK granting a tumor agnostic label I would think the regulators would see the system totally overwhelmed in the UK alone without the EDEN being approved. With GBM alone the demand there will be high for the vaccine, if I remember correctly they have over 3 times the patients discovered with GBM there then Sawston can deliver. But if they got a tumor agnostic label the demand might be 50 to 100 times what could be supplied.
It's very possible the approvals are on parallel paths and the vaccine could come first. In the back of my mind I think if that's the case the UK regulators want to be certain that the EDEN will follow very shortly behind.
Gary
Bullish
Market Data 
Markets 
AI
